Price Jackson
Overview
Explore the profile of Price Jackson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1258
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Assessment of cervical spine CT by an image quality audit using qualitative and quantitative methods
Bajwa H, Sritharan T, Botha T, Jackson P, McAnulty K, Lim L, et al.
J Med Imaging Radiat Oncol
. 2024 Nov;
69(1):7-16.
PMID: 39482850
Introduction: To study the feasibility and assess the correlation of qualitative and quantitative methods for an image quality (IQ) audit of a Cervical spine CT. Methods: Five radiologists retrospectively performed...
2.
Buteau J, Kostos L, Alipour R, Jackson P, McInstosh L, Emmerson B, et al.
J Nucl Med
. 2024 Jul;
65(8):1231-1238.
PMID: 38991752
[Lu]Lu-PSMA is an effective class of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC); however, progression is inevitable. The limited durability of response may be partially explained by the...
3.
Ayati N, Mcintosh L, Buteau J, Alipour R, Pudis M, Daw N, et al.
Cancer Imaging
. 2024 May;
24(1):57.
PMID: 38711135
Background: PSMA PET/CT is a predictive and prognostic biomarker for determining response to [Lu]Lu-PSMA-617 in patients with metastatic castration resistant prostate cancer (mCRPC). Thresholds defined to date may not be...
4.
Gaudreault M, Hardcastle N, Jackson P, Mcintosh L, Higgs B, Pryor D, et al.
Int J Radiat Oncol Biol Phys
. 2024 Apr;
120(3):648-654.
PMID: 38679212
Purpose: Stereotactic ablative body radiotherapy (SABR) is a novel option to treat primary renal cell carcinoma. However, a high radiation dose may be received by the treated kidney, which may...
5.
Mcintosh L, Jackson P, Emmerson B, Buteau J, Alipour R, Kong G, et al.
EJNMMI Phys
. 2024 Feb;
11(1):18.
PMID: 38372952
Background: Terbium-161 (Tb)-based radionuclide therapy poses an alternative to current Lutetium-177 (Lu) approaches with the additional benefit of secondary Auger and conversion electron emissions capable of delivering high doses of...
6.
Krokos G, Kotwal T, Malaih A, Barrington S, Jackson P, Hicks R, et al.
Biomed Phys Eng Express
. 2023 Dec;
10(2).
PMID: 38100790
Utilisation of whole organ volumes to extract anatomical and functional information from computed tomography (CT) and positron emission tomography (PET) images may provide key information for the treatment and follow-up...
7.
Eapen R, Buteau J, Jackson P, Mitchell C, Oon S, Alghazo O, et al.
Eur Urol
. 2023 Oct;
85(3):217-226.
PMID: 37891072
Background: High-risk localised prostate cancer (HRCaP) has high rates of biochemical recurrence; [Lu]Lu-PSMA-617 is effective in men with advanced prostate cancer. Objective: To investigate the dosimetry, safety, and efficacy of...
8.
Sutherland D, Kashyap R, Jackson P, Buteau J, Murphy D, Kelly B, et al.
Ther Adv Med Oncol
. 2023 Jun;
15:17588359231177018.
PMID: 37323189
Reported here is a case of rapidly progressive metastatic castration-resistant prostate cancer treated with [Lu]Lu-PSMA-617 in the setting of severe renal impairment and impending ureteric obstruction. PSMA is expressed on...
9.
Gaudreault M, Chang D, Hardcastle N, Jackson P, Kron T, Hofman M, et al.
Front Oncol
. 2023 Mar;
13:1134884.
PMID: 36994211
Background: Lutetium-177 [Lu]-PSMA-617 is a targeted radioligand that binds to prostate-specific membrane antigen (PSMA) and delivers radiation to metastatic prostate cancer. The presence of PSMA-negative/FDG-positive metastases can preclude patients from...
10.
Gaudreault M, Chang D, Hardcastle N, Mcintosh L, Jackson P, Kron T, et al.
Clin Transl Radiat Oncol
. 2023 Mar;
40:100608.
PMID: 36942088
Background: Biology-guided radiotherapy (BgRT) is a novel treatment where the detection of positron emission originating from a volume called the biological tracking zone (BTZ) initiates dose delivery. Prostate-specific membrane antigen...